2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
22
Neoplasms
15
Pulmonary Embolism
10
Venous Thrombosis
9
Thrombosis
6
Multiple Myeloma
4
Upper Extremity Deep Vein Thrombosis
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Lymphoma
2
Intracranial Thrombosis
2
Hematologic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Mesenteric Ischemia
1
Leukemia
1
Head and Neck Neoplasms
1
Interventions
Temozolomide
159
Bevacizumab
69
Radiotherapy
68
Magnetic Resonance Spectroscopy
68
Irinotecan
31
Surgical Procedures, Operative
27
Radiation
24
Carboplatin
23
Specimen Handling
20
Carmustine
20
Blood Specimen Collection
20
Nivolumab
19
Aminolevulinic Acid
18
Biopsy
17
Lomustine
16
pembrolizumab
13
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
13
trametinib
12
fluorodopa F 18
12
X-Rays
12
Radiosurgery
12
Erlotinib Hydrochloride
12
Topotecan
11
Everolimus
11
Magnetic Resonance Imaging
10
IL13-PE38
10
dabrafenib
9
Etoposide
9
Drug Therapy
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
apixaban
×
Clear all
NCT05683808
2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2
Recruiting
40 enrolled